University Of New Mexico Albuquerque

SANTA FE, N.M. — In this video exclusive, E. Michael Lewiecki, MD, FACE, FACP, describes Bone Health ECHO, a virtual community of physicians who review osteoporosis and bone-disease cases together each week via video conferencing.

During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back.

SAN DIEGO — Patients with low bone density may have osteoporosis despite registering a bone mineral density score higher than –2.5, according to a speaker at the Congress of Clinical Rheumatology West

Hydrocortisone administered to extremely preterm infants who remained intubated at 14 to 28 days failed to improve survival without moderate or severe bronchopulmonary dysplasia at 36 weeks’ postmenstrual age compared with placebo.

SAN DIEGO — Understanding the factors known to predict physician burnout, and implementing interventions, can help prevent and reduce the condition, which affects more than half of physicians, according to a presenter at the ACP Internal Medicine Meeting.

Premature death rates in the United States differ by race and ethnicity, showing a decline among Hispanics, blacks and Asian/Pacific Islanders and an increase among whites and American Indian/Alaska Natives between 1999 to 2014, according to a news release issued by the NIH.

The FDA’s Pulmonary-Allergy Drugs Advisory Committee voted to ban codeine-combination medication sold over-the-counter and to contraindicate the medication for children aged younger than 18 years as both a painkiller and as cough medicine.

The FDA has granted 510(k) clearance to the cobas Cdiff Test for detection of Clostridium difficile in stool specimens, the manufacturer announced today.

TORONTO — The clinical benefits of minimally invasive and robotic mitral valve surgery are comparable; however, the robotic procedure is associated with higher costs, according to a new report.

Risperidone (Risperdal) was approved to treat schizophrenia in 2002 and for the short-term treatment of mania and mixed episodes associated with bipolar 1 disorder in 2003. In March 2002, however, Janssen, a Johnson & Johnson company, began marketing the drug as a safe and effective treatment for agitation associated with dementia in the elderly — an indication and subpopulation the drug was not approved to treat.